Wegovy: A New Weight Loss Medication in Canada

Wegovy, a weight loss medication manufactured by Novo Nordisk, has recently become available in Canada. This drug contains semaglutide, the same active ingredient found in Ozempic. As a member of the GLP-1 analogue class of medicines, Wegovy was originally designed to control blood sugar but has also proven effective for weight loss by promoting feelings of fullness.

One of the key differences between Wegovy and Ozempic is the dosage. Wegovy contains a higher dose of semaglutide, with a maximum of 2.4 mg per week, compared to Ozempic’s maximum of 1 mg per week. While Ozempic is primarily used for treating Type 2 diabetes, Wegovy is specifically approved for chronic weight management.

Wegovy is recommended for individuals who have a body mass index (BMI) of 27 or higher and at least one weight-related condition, such as high blood pressure, Type 2 diabetes, or high cholesterol. It is particularly suited for those looking for an effective obesity treatment and who are willing to combine the medication with a reduced-calorie diet and increased physical activity.

However, Wegovy may not be appropriate for everyone, so it is important to ask who should and who shouldn’t use it. It is not intended for individuals seeking to lose a few pounds for cosmetic reasons or those who have only temporarily gained weight.

Potential drawbacks of using Wegovy include common side effects such as nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, and dizziness. Additionally, the cost of treatment is significant—approximately C$4,726 per patient per year—which may not be covered by public insurance plans. It could take time for private insurance plans to include coverage for this medication.

Dr. Sanjeev Sockalingam of Obesity Canada emphasizes that Wegovy is a medical treatment for obesity rather than a quick fix for minor weight loss. The availability of Wegovy is seen as a positive development in addressing obesity in Canada, where one in four adults is affected by this condition and faces associated chronic health issues.